Your search

Early detection of prostate cancer is critical for the success of cancer therapy. It is believed that the biochemical changes that cause the optical spectra changes would appear earlier than the histological aberration. The aim of this ex vivo study was to evaluate the ability of Stokes Shift Spectra (S3) to identify human prostate cancerous tissues from the normal. Fifteen (15) pairs of with pathologically confirmed human prostate cancerous and normal tissues underwent Stokes Shift Spectra measurements with selective wavelength interval of 40 nm. The spectra were then analyzed using machine learning (ML) algorithms to classify the two types of tissues. The ML algorithms including principal component analysis (PCA) and nonnegative matrix factorization (NMF) were used for dimension reduction and feature detection. The characteristic component spectra were used to identify the key fluorophores related to carcinogenesis. The results show that these key fluorophores within tissue, e.g., tryptophan, collagen, and NADH, have different relative concentrations between cancerous and normal tissues. A multi-class classification was performed using support vector machines (SVMs). A leave-one-out cross validation was used to evaluate the performance of the classification with the gold standard histopathological results as the ground truth. The results with high sensitivity and specificity indicate that the S3 method is effective for detecting changes of fluorophore composition in human prostate tissues due to the development of cancer. © 2021 SPIE.

The unique advantage of visible resonance Raman (VRR) spectroscopy using 532 nm excitation wavelength for biological samples is the resonance enhancement of vibrational modes of chemical bonds from cells and tissues. The aim of this study is specifically to reveal the VRR characteristic spectra of different organs in mice, find the molecular alterations in the development of white matter and gray matter of mouse embryos at different ages and study the VRR spectral information of the mouse embryo head using VRR technology.

There is still a lack of reliable intraoperative tools for glioma diagnosis and to guide the maximal safe resection of glioma. We report continuing work on the optical biopsy method to detect glioma grades and assess glioma boundaries intraoperatively using the VRR-LRRTM Raman analyzer, which is based on the visible resonance Raman spectroscopy (VRR) technique. A total of 2220 VRR spectra were collected during surgeries from 63 unprocessed fresh glioma tissues using the VRR-LRRTM Raman analyzer. After the VRR spectral analysis, we found differences in the native molecules in the fingerprint region and in the high-wavenumber region, and differences between normal (control) and different grades of glioma tissues. A principal component analysis–support vector machine (PCA-SVM) machine learning method was used to distinguish glioma tissues from normal tissues and different glioma grades. The accuracy in identifying glioma from normal tissue was over 80%, compared with the gold standard of histopathology reports of glioma. The VRR-LRRTM Raman analyzer may be a new label-free, real-time optical molecular pathology tool aiding in the intraoperative detection of glioma and identification of tumor boundaries, thus helping to guide maximal safe glioma removal and adjacent healthy tissue preservation.

Machine learning algorithms were used to classify and analyze spectral data collected by visible resonance Raman spectroscopy to distinguish normal human brain tissue and glioma tumor tissues at different grades and show promising results. © OSA 2020 © 2020 The Author(s)

Recent reports pointed out that the application of optical spectroscopy in the field of liquid biopsy has aroused great interest among researchers and demonstrated the potential of its clinical application. We report a preliminary investigation on the visible resonance Raman (VRR) spectra of human brain blood liquid collected from the scalp and around the meningeal tumor during surgery and a set of venous blood samples from healthy people and glioma grade III patients using a portable VRR-LRRTM, HR800, HR-Evolution and WITec300 Raman systems in vivo and ex vivo. The biochemical fingerprints and molecular biomarkers were found. These findings indicate that if VRR spectroscopy technology is combined with polymerase chain reaction (PCR) or genetic molecular biomarker methods (VRR-PCR), it will greatly increase the possibility for its clinical application. © 2021 SPIE.

Alzheimer’s disease (AD) pathogenesis is widely believed to be associated with the production and deposition of the β-amyloid peptide (Aβ) and neurofibrillary tangles (NFTs) which are composed of a highly-phosphorylated form of the microtubule-associated protein tau. Based on the above hypothesis, there are currently no sufficiently effective technologies and drugs for early detection and treatment of AD. Even the most promising new drug Lecanemab that is based on an anti-amyloid monoclonal antibody therapy, has only partially slowed down the cognitive performance of patients with mild impairment caused by Alzheimer's disease. The main symptoms of AD brain tissue lesions in patients are the deposition of β-amyloid peptide and the hyperphosphorylation of tau protein, which aggregates the microtubule structure of neurons. Therefore, Aβ deposition and hyperphosphorylation of Tau are important pathological biomarkers of Alzheimer's disease. Therefore, the main targets of research for AD prevention, detection and pharmaceuticals are still Aβ and Tau protein. The aim of this study was to detect the changes of Aβ and Tau proteins in the mouse brain tissue with AD and control samples using Visible Resonance Raman (VRR) spectroscopic technology. An attempt was made to develop criteria for the detection of early AD lesions by optical spectroscopy technology. The VRR spectra of AD, the control mouse brain tissues, and Aβ and Tau proteins were recorded and analyzed. The AD and the control mouse brain tissue samples were selected from the thalamus, frontal lobe cortex and hippocampus brain areas. VRR technology with high spatial resolution and the resonance-enhanced features of certain protein molecules is first used in this study to detect and characterize the changes of Aβ and Tau proteins in AD mouse brain model. The optical spectroscopy biomarkers of AD and Control brain tissue were identified in fingerprint and the high-wavenumber regions. The Raman spectra of the secondary structure of protein in amide (I-II-III-B-A) are detected and analyzed. The results indicate that the intensity of Amide I decreased at the 1666 cm^-1 corresponding to the β-sheet structure, and the intensity of the amide III bands (1220- 1320 cm^-1) increased in all AD brain tissues. It was also observed that the Raman peaks of 1448 and 980 cm^-1 related to the abundance of proline, serine, and threonine at tau phosphorylation sites were significantly enhanced in the frontal lobe cortex and hippocampus of AD brain tissues. The intensity ratio biomarker of high phosphorylation in the high wavenumber range from 2898 to 2932 cm-1 increased in all AD brain tissues. Changes of protein secondary conformation and abnormally phosphorylated tau or tauopathies were observed. In summary, VRR is a sensitive tool for characterizing protein structural changes and monitoring the tau phosphorylation. It may potentially be used for early detection of AD.

Based on Visible Resonance Raman (VRR) method, we have developed a novel label-free portable VRR LRR2000 Raman analyzer with a portable fiber-optic probe and used it for the classification of human gliomas ex vivo and for the analysis of changes in tumor chemical compositions in molecular level. The purpose of this study was to examine the performance of the LRR2000 Raman analyzer as an optical biopsy tool for detecting human brain tumors compared to the commercial laboratory HR800 and WITec300 micro confocal Raman spectroscopy instruments. As of 2018, a total 1,938 VRR spectra were collected using LRR2000, HR800 and WITec300 Raman system, ex vivo. Identification of the four grades of glioma tumors and control tissues was performed based on the characteristic native molecular fingerprints. LRR2000 demonstrated consistent diagnostic results with HR800 and WITec300 Raman systems. LRR2000 showed the advantages of high speed, convenience and low cost compared to the two confocal micro Raman systems. Using artificial intelligence (AI)-based analysis of part of the data, the cross-validated accuracy for identifying glioma tumors is ~90% compared with gold standard histopathology examination.